NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting Soligenix Inc’s (Nasdaq: SNGX) key achievements and pathway to regulatory success through its lead product candidate, HyBryteTM (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma, a rare and chronic cancer. Soligenix is targeting a CTCL therapeutics market that in 2023. The company is working towards initiating a confirmatory Phase 3 placebo-controlled study, FLASH2, to replicate the results of Soligenix’s successful Phase 3 FLASH trial.
This targeted replication study is expected to enroll approximately 80 patients in the U.S. and Europe, beginning by the end of 2024, with top-line results anticipated in the second half of 2026.
Dr. Christopher J. Schaber, President and Chief Executive Officer of Soligenix, told PRISM MarketView that FLASH2 is expected to have a higher probability of success, with a more robust response.
In addition, the company expects to enroll more rapidly than in the first FLASH study due to Soligenix's significant experience with U.S. CTCL clinical sites and the ability to potentially enroll patients from the first trial.
In conversation with PRISM MarketView, Dr. Schaber said that the corporate objectives for the continued studies were to reinforce and replicate the positive HyBryteTM data from the FLASH study. “We look forward to continuing to work with Dr.
Poli.
